These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 29759770)
21. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib. Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233 [TBL] [Abstract][Full Text] [Related]
22. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Tran PN; O'Brien S Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951 [TBL] [Abstract][Full Text] [Related]
23. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152 [No Abstract] [Full Text] [Related]
24. New approved indication for ibrutinib. Aschenbrenner DS Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579 [No Abstract] [Full Text] [Related]
26. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510 [No Abstract] [Full Text] [Related]
27. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309 [TBL] [Abstract][Full Text] [Related]
28. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603 [TBL] [Abstract][Full Text] [Related]
29. [Ibrutinib: A new drug of B-cell malignancies]. Thieblemont C Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882 [TBL] [Abstract][Full Text] [Related]
30. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970 [TBL] [Abstract][Full Text] [Related]
31. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246 [No Abstract] [Full Text] [Related]
32. How I treat CLL patients with ibrutinib. Brown JR Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067 [TBL] [Abstract][Full Text] [Related]
33. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653 [TBL] [Abstract][Full Text] [Related]
34. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945 [TBL] [Abstract][Full Text] [Related]
35. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. Faisal MS; Shaikh H; Khattab A; Albrethsen M; Fazal S J Oncol Pharm Pract; 2019 Sep; 25(6):1486-1490. PubMed ID: 30045683 [TBL] [Abstract][Full Text] [Related]
36. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233 [TBL] [Abstract][Full Text] [Related]
37. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature. Titus-Rains KS; Brown JN; Hammond JM J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377 [TBL] [Abstract][Full Text] [Related]
38. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511 [TBL] [Abstract][Full Text] [Related]
39. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921 [TBL] [Abstract][Full Text] [Related]